Ajinomoto (2802) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
30 Jun, 2026Executive summary
Sales, business profit, and profit attributable to owners reached new record highs for the first three quarters of FY2025, with strong acceleration in the third quarter and robust performance in both domestic and overseas markets.
Upward revisions were made to full-year forecasts for business profit and profit attributable to owners, driven by strong segment performance and gains from asset sales.
Strategic focus for FY2026 includes accelerating growth in Bio & Fine Chemicals and achieving 2030 Roadmap targets ahead of schedule.
Financial highlights
Cumulative Q3 FY2025 sales reached ¥1,164.1 billion (101% YoY), business profit ¥145.9 billion (105% YoY), and profit attributable to owners ¥89.7 billion (108% YoY).
Q3 FY2025 sales were ¥425.2 billion (104% YoY), business profit ¥59.2 billion (115% YoY), and profit attributable to owners ¥38.5 billion (119% YoY).
FY2025 revised full-year forecast: sales ¥1,600 billion (104% YoY), business profit ¥181 billion (113% YoY), profit attributable to owners ¥130 billion (184% YoY).
Gross profit for the nine months was ¥445.4 billion, up from ¥422.0 billion year-over-year.
Basic earnings per share increased to ¥91.82 from ¥81.54 year-over-year.
Outlook and guidance
Full-year FY2025 business profit and profit attributable to owners are revised upward, with sales forecast slightly reduced due to currency effects and lower expectations in some segments.
FY2026 targets include continued growth in Seasonings and Foods and dramatic expansion in Bio & Fine Chemicals.
The company aims to achieve its 2030 roadmap targets ahead of schedule, focusing on sustainable growth in core segments and targeting approximately 3x EPS versus FY2022 and ROE of approximately 17%.
Latest events from Ajinomoto
- Amino acid innovation powers global growth, health, and sustainability, with strong returns.2802
Corporate presentation - Record Q1 sales and profit led to upward full-year guidance amid strong electronic materials demand.2802
Q1 2027 - Marketing and digital transformation drive ambitious 2030 growth, brand, and ESG targets.2802
Investor update - Global leader in amino acid science targets growth, health impact, and major sustainability gains.2802
Investor presentation - AI-driven demand and innovation boost ABF growth, margins, and capacity expansion.2802
Investor update - Doubling medical food sales by 2030 through 20%+ growth, innovation, and global expansion.2802
Investor update - CDMO revenue is set to triple by FY2030 as Forge Biologics drives gene therapy growth.2802
Investor Day 2024 - Sales up 7.7% with record profit, but net profit fell 12% on tax; guidance unchanged.2802
Q1 2025 - Record sales and profit growth led to upward forecasts and increased shareholder returns.2802
Q2 2025